The Quick Answer
Gabapentin and pregabalin work by the same mechanism (alpha-2-delta calcium channel binding) and have similar efficacy for neuropathic pain. Pregabalin has more predictable absorption and is FDA-approved for more indications. Gabapentin is generally cheaper. The choice often comes down to cost, insurance coverage, and individual tolerability.
Side-by-Side Comparison
| Feature | Gabapentin (Neurontin) | Pregabalin (Lyrica) |
|---|---|---|
| Brand name | Neurontin, Gralise, Horizant | Lyrica, Lyrica CR |
| Generic available | Yes (since 2004) | Yes (since 2019) |
| Generic cost | $10–$30/month | $20–$60/month |
| Mechanism | Alpha-2-delta calcium channel binding | Alpha-2-delta calcium channel binding |
| Absorption | Non-linear (saturable); variable at high doses | Linear; predictable at all doses |
| Bioavailability | 27–60% (dose-dependent) | ~90% (dose-independent) |
| Dosing frequency | 3 times daily (TID) | 2–3 times daily |
| FDA-approved indications | Epilepsy, PHN, RLS (Horizant) | Epilepsy, PHN, DPN, fibromyalgia, spinal cord injury pain |
| Schedule | Not federally scheduled (some states: Schedule V) | Schedule V (federal) |
| Abuse potential | Moderate (increasingly recognized) | Moderate (federally scheduled) |
Key Pharmacological Difference: Absorption
The most important pharmacological difference between gabapentin and pregabalin is their absorption profile. Gabapentin is absorbed via a saturable amino acid transporter in the gut (LAT1). At low doses, absorption is relatively good (~60%), but at higher doses, the transporter becomes saturated and absorption decreases — sometimes to as low as 27%. This non-linear absorption makes dose titration less predictable.
Pregabalin is absorbed by the same transporter but at a lower affinity, meaning it is not saturated at therapeutic doses. Pregabalin achieves approximately 90% bioavailability regardless of dose, making it more predictable and potentially more effective at higher doses.
FDA-Approved Indications: Pregabalin Has More
| Indication | Gabapentin | Pregabalin |
|---|---|---|
| Partial seizures (adjunct) | ✅ Approved | ✅ Approved |
| Postherpetic neuralgia (PHN) | ✅ Approved | ✅ Approved |
| Diabetic peripheral neuropathy (DPN) | ❌ Off-label | ✅ Approved |
| Fibromyalgia | ❌ Off-label | ✅ Approved |
| Spinal cord injury pain | ❌ Off-label | ✅ Approved |
| Restless legs syndrome | ✅ Approved (Horizant ER only) | ❌ Off-label |
| Generalized anxiety disorder | ❌ Off-label | ✅ Approved in EU (not US) |
Efficacy: Are They Equally Effective?
Head-to-head trials comparing gabapentin and pregabalin are limited. Most evidence comes from separate placebo-controlled trials, which show similar effect sizes for neuropathic pain and fibromyalgia. A 2019 Cochrane review found both drugs provide meaningful pain relief in approximately 30–40% of patients with neuropathic pain (defined as ≥50% pain reduction).
Pregabalin may be more effective at higher doses due to its linear absorption, but this advantage is often offset by increased side effects. For most patients, the drugs are clinically interchangeable for efficacy.
Side Effects: Largely Similar
Both drugs have similar side effect profiles: somnolence, dizziness, peripheral edema, weight gain, and cognitive effects. Pregabalin may cause slightly more weight gain and peripheral edema due to its higher bioavailability. Both carry FDA boxed warnings for respiratory depression when combined with CNS depressants.
Abuse Potential and Scheduling
Pregabalin is federally scheduled as Schedule V due to its abuse potential. Gabapentin is not federally scheduled but is classified as Schedule V in several states. Both drugs can produce euphoria and are misused, particularly in combination with opioids. Pregabalin's higher bioavailability and faster onset may make it slightly more reinforcing than gabapentin.
How to Choose
| Situation | Preferred Choice | Reason |
|---|---|---|
| Cost is a priority | Gabapentin | Cheaper generic; available since 2004 |
| Fibromyalgia | Pregabalin | FDA-approved; stronger evidence base |
| Diabetic neuropathy | Pregabalin | FDA-approved; predictable dosing |
| Postherpetic neuralgia | Either | Both FDA-approved; similar efficacy |
| High doses needed | Pregabalin | Linear absorption; more predictable at high doses |
| Insurance covers one but not other | Whichever is covered | Both are effective |
References
- Derry S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1:CD007076.
- Wiffen PJ, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938.
- Bockbrader HN, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661-669.
Save up to 80% on this medication
Use a free RxGo discount card at 67,000+ pharmacies — no sign-up, no insurance needed.
About the Author
James Okafor, RPh, MBA
Registered Pharmacist & Health Economics Writer
James Okafor is a registered pharmacist with over 12 years of experience in retail and clinical pharmacy settings. He holds an MBA with a focus on healthcare management and specializes in translating complex drug pricing, formulary, and insurance coverage topics into clear, actionable guidance for patients. Before joining RxGuide, James worked as a clinical pharmacist at a regional hospital system and as a pharmacy benefits consultant for a national PBM. His writing focuses on cost transparency, generic alternatives, and helping patients navigate the U.S. prescription drug system.
View full profile on our Editorial Team page →Get the RxGo app — free prescription discounts on the go
Works at 67,000+ pharmacies · No membership needed